Credit: Milestone Pharmaceuticals. Each nasal spray device delivers 2 sprays containing a total of etripamil 70mg. The intranasal therapy consists of a novel calcium channel blocker and is designed to ...
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Monday that its recently approved CARDAMYST (etripamil) nasal spray is now available through U.S. retail pharmacies for ...
FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of. Mr. Sandoval’s appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved ...
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that CARDAMYST, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia, is now ...
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially ...
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance ...
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially ...
AptarGroup, Inc. (NYSE:ATR) Q4 2025 Earnings Call Transcript February 6, 2026 Operator: Ladies and gentlemen, thank you for ...
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results